-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2023
Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Drugs In Development, 2023’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986178 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986178 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986178 in B-Cell Non-Hodgkin Lymphoma Drug Details: BMS-986178 is under development...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Efinopegdutide
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Veru Inc’s Enobosarm
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VTX-958 in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VTX-958 in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VTX-958 in Crohn's Disease (Regional Enteritis) Drug Details: VTX-958 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VTX-958 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VTX-958 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VTX-958 in Systemic Lupus Erythematosus Drug Details: VTX-958 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IO-112 in Essential Thrombocythemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IO-112 in Essential Thrombocythemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IO-112 in Essential Thrombocythemia Drug Details: IO-112 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VTX-002 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VTX-002 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.VTX-002 in Ulcerative Colitis Drug Details:VTX-002 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-6793 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AZD-6793 in Inflammation Drug Details:AZD-6793 is under development for the treatment of inflammatory diseases. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VTX-3232 in Neuroinflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VTX-3232 in Neuroinflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VTX-3232 in Neuroinflammation Drug Details: VTX-3232 is under development for the treatment...